Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11490824 | 1.00 | FKBP1A (0.49) | FKBP1AALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL11490823 | 1.00 | FKBP1A (0.49) | FKBP1AALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL24846753 | 0.95 | FKBP1A (0.55) | FKBP1AALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL652160 | 0.95 | FKBP1A (0.55) | FKBP1AALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL19576693 | 0.86 | FKBP1A (0.51) | FKBP1AALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL13601739 | 0.86 | PPM1B (0.41) | FKBP1ACYP3A4CYP2D6 | |
| SCHEMBL13601762 | 0.86 | PPM1B (0.41) | FKBP1ACYP3A4CYP2D6 | |
| SCHEMBL29142204 | 0.85 | CYP3A4 (0.39) | FKBP1AALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL7262161 | 0.84 | FKBP1A (0.46) | FKBP1A | |
| SCHEMBL14645015 | 0.84 | CYP3A4 (0.38) | FKBP1ACYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2019-06-27 | — | — | US | disclosed |
| WO-2018037223-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2018-03-01 | — | — | WO | disclosed |
| US-7625886-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | B3GNT2, RPN2, RPN1 | FKBP1A 932/4885ALDH1A1 3333/4885MAPT 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.